STOCK TITAN
  1. Home
  2. News
  3. ABUS

Arbutus Biopharma Corp - ABUS STOCK NEWS

Welcome to our dedicated news page for Arbutus Biopharma (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arbutus Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arbutus Biopharma's position in the market.

News
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
Rhea-AI Summary
Arbutus Biopharma (Nasdaq: ABUS) will report its first quarter 2024 financial results and provide a corporate update on May 2, 2024. The company aims to develop a functional cure for chronic hepatitis B virus infection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
Rhea-AI Summary
Arbutus Biopharma (ABUS) issues a statement on the claim construction ruling by the U.S. District Court regarding the lawsuit against Moderna, Inc. The Court's Opinion addresses key patent claims related to Moderna's COVID-19 vaccine, MRNA-1273.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none
-
News
Arbutus to Participate in Two Upcoming Investor Conferences
Rhea-AI Summary
Arbutus Biopharma Corporation (ABUS) announced participation in investor conferences to discuss its progress in developing a functional cure for chronic hepatitis B virus infection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
conferences
News
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Arbutus Biopharma Corporation (Nasdaq: ABUS) reports strong financial position with cash and investments of $132M, plans for key clinical data in 2024, and ongoing Phase 2a trials with imdusiran and AB-101.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
earnings
-
News
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
Rhea-AI Summary
Arbutus Biopharma Corporation (ABUS) announced the schedule for its Q4 and year-end 2023 financial results and corporate update, set for February 29, 2024. The company aims to develop a functional cure for chronic hepatitis B virus infection leveraging its virology expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
Rhea-AI Summary
Arbutus Biopharma Corporation (ABUS) announced its 2024 business outlook, including clinical development milestones for its HBV pipeline and a financial update. The company's strong balance sheet and anticipated clinical trial readouts position it well towards achieving its mission of developing a functional cure for patients with chronic hepatitis B virus (cHBV). The Phase 2a program for imdusiran, the company's RNAi therapeutic, reinforces the potential role of imdusiran as a cornerstone in a treatment regimen to functionally cure patients with cHBV. Additionally, AB-101, the company's oral PD-L1 inhibitor, continues to progress, with preliminary data expected from the ongoing Phase 1a/1b clinical trial. Arbutus also provided an update on the claim construction hearing for Moderna LNP litigation and its strong financial position with a cash runway into Q1 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
none
News
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
Rhea-AI Summary
Arbutus Biopharma Corporation (ABUS) and Barinthus Biotherapeutics plc (BRNS) announced a late breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, presenting preliminary data from the Phase 2a clinical trial (AB-729-202) combining Arbutus’ RNAi therapeutic, imdusiran, with Barinthus Bio's T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide analogue (NA) therapy. The data showed a meaningful reduction of HBsAg levels, robust reductions of HBsAg during the imdusiran treatment period, and preliminary immunology data suggesting HBV-specific T cell IFN-γ production is enhanced in patients receiving imdusiran plus VTP-300 compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
clinical trial
-
News
Arbutus to Present at Jefferies London Healthcare Conference
Rhea-AI Summary
Arbutus Biopharma Corporation (ABUS) announced their participation in the Jefferies London Healthcare Conference on November 15, 2023, presenting their efforts in developing a cure for chronic hepatitis B virus (cHBV) infection. The live webcast of the presentation can be accessed at https://investor.arbutusbio.com/events-presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
conferences
-
News
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported third-quarter 2023 financial results and provided a corporate update. They will be presenting preliminary data at AASLD from the first group of patients in its Phase 2a clinical trial evaluating imdusiran, nucleos(t)ide analogue (NA) therapy, and VTP-300, an HBV antigen-specific immunotherapy. Dosing continues in two Phase 2a combination clinical trials with imdusiran and in a Phase 1a/1b clinical trial with AB-101, their oral PD-L1 checkpoint inhibitor. They are reducing their workforce by 24% as a result of recent pipeline optimization. The cash runway has been extended into the first quarter of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
earnings
News
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
Rhea-AI Summary
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that William Collier will retire from his position as President and CEO, with Michael J. McElhaugh, Co-founder and COO, stepping in as Interim CEO effective January 1, 2024. The company expressed gratitude for Collier's leadership and confidence in McElhaugh's ability to advance Arbutus' pipeline and shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
none
Stock ABUS logo
Arbutus Biopharma Corp

Nasdaq:ABUS

ABUS Rankings

#2979 Ranked by Market Cap
#3662 Ranked by Stock Gains
N/A Ranked by Dividends

ABUS Stock Data

526.11M
115.80M
23.34%
43.89%
2.53%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Warminster

About ABUS

arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.